Table 2. Summary of data including the results of the receptors and MMR immunostains, and Fisher’s Exact tests.
| Diagnosis | n | ER | PR | AR | MMR | ||||
|---|---|---|---|---|---|---|---|---|---|
| +n | +% | +n | +% | +n | +% | +n | +% | ||
| EEC | 36 | 35 | 97% | 35 | 97% | 35 | 97% | 6 | 17% |
| NEEC | 26 | 11 | 42% | 7 | 27% | 17 | 65% | 3 | 12% |
| SCA | 10 | 8 | 80% | 5 | 50% | 9 | 90% | 0 | 0% |
| CCCA | 5 | 0 | 0% | 0 | 0% | 3 | 60% | 0 | 0% |
| CS | 5 | 3 | 60% | 2 | 40% | 5 | 100% | 0 | 0% |
| DECA | 5 | 0 | 0% | 0 | 0% | 0 | 0% | 3 | 60% |
| MNCA | 1 | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% |
| Met | 4 | 4 | 100% | 3 | 75% | 4 | 100% | 2 | 50% |
| All | 66 | 50 | 76% | 45 | 68% | 56 | 85% | 11 | 17% |
| 2x2 Contingency Table Values | Fisher’s Exact Test P-Values | ||||||||
| Positive | Negative | ER vs MMR | PR vs MMR | AR vs MMR | |||||
| EEC | ER | 35 | 1 | <0.0001 | |||||
| PR | 35 | 1 | <0.0001 | <0.0001 | |||||
| AR | 35 | 1 | |||||||
| MMR | 6 | 30 | |||||||
| NEEC | ER | 11 | 15 | 0.3 | |||||
| PR | 7 | 19 | 0.03 | 0.0001 | |||||
| AR | 17 | 9 | |||||||
| MMR | 3 | 23 | |||||||
| Met | ER | 4 | 0 | 1 | |||||
| PR | 3 | 1 | 0.4 | 0.4 | |||||
| AR | 4 | 0 | |||||||
| MMR | 2 | 2 | |||||||
| All | ER | 50 | 16 | <0.0001 | |||||
| PR | 45 | 21 | <0.0001 | <0.0001 | |||||
| AR | 56 | 10 | |||||||
| MMR | 11 | 55 | |||||||
ER, estrogen receptor; PR, progesterone receptor; +, positive reaction; AR, androgen receptor; EEC, endometrial endometrioid cancer; NEEC, non-endometrioid endometrial cancers which includes: SCA, serous carcinoma; CCCA, clear cell carcinoma; CS, carcinosarcoma; DECA, dedifferentiated endometrial carcinoma; and MNCA, mesonephric like carcinoma; Met, metastatic carcinoma; MMR, mismatch repair, loss as positive, intact as negative.